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Introduction
A big problem facing the world today is the rise of obesity. 
According to the CDC, approximately one third of the American 
adult population is obese. Obesity is characterized by a Body 
Mass Index (BMI), of 30 or higher, while healthy weight BMI is in 
the range of 18.5-24.9 (CDC, 2012). One possible con-sequence 
of obesity is the development of type 2 diabetes. Diabetes is a 
disease characterized by elevated glucose levels as a result of 
insufficient insulin production or a malfunctioning insulin system. 
Of the Americans population 29.1 million or 9.3%, had diabetes 
in 2012. This number was an increase from 2010 when the statis-
tics were 25.8 million and 8.3% (American Diabetes Association, 
2014). In type 1 diabetes mellitus, the β cells of the pancreas that 
are responsible for producing insulin are destroyed. In the ab-
sence of insulin, these individuals are at risk for hyperglycemia, or 
dangerously elevated blood glucose levels. Type 2 diabetes usually 
has a later onset. People with type 2 diabetes experience insulin 
resistance so that the insulin does not help glucose enter the 
body cells. Eventually the body stops producing insulin altogether 
(CDC, 2014). Most cases of diabetes, 90-95% are type 2 diabetes. 
Statistics show that 90% of cases of type 2 diabetes in western 
countries can be attributed to excess weight gain or obesity. 
Improving glucose tolerance while losing weight is the aim of 
new treatments for diabetes. Examining the effects the hormone 
ghrelin has on glucose metabolism can be a valuable therapeutic 
option (Rudolph, et al. 2007). Ghrelin is a 28 amino acid peptide 
hormone that plays a role in many different body functions. It is 
the endogenous ligand for the growth hormone secretagogue 
receptor (GHS-R) and has been proven to increase growth hor-
mone secretion. Additionally, ghrelin is known as an orexigenic, or 
appetite-stimulating hormone, and is also responsible for energy 
bal-ance. It is produced predominantly in the stomach but is also 
produced in other places including the pancreas. One important 
function ghrelin serves is the ability to control insulin release 
from β cells of the pancreas. In the presence of ghrelin, insulin 
secretion is reduced, and blood glucose concentration increases. 
Research shows the effect of ghrelin on pancreatic islet β-cells. 
Ghrelin suppresses insulin secretion from β-cells by interfering 
with the K and Ca2+ channels that are stimulated by glucose 
metabolism. Obese individuals and diabetics have lower levels of 
plasma ghrelin than lean individuals. It is reasonable to suggest 
that this may be a regulated response in order to minimize the 
ghrelin activity that reinforces obesity. Subsequent research im-
plicated possible regulation of ghrelin to treat obesity and diabe-
tes. Since insulin levels are decreased in the presence of ghrelin, 
investigation of techniques to reduce or diminish the effects of 
ghrelin is in effect. Various treatment options that have under-
gone research and experimentation show posi-tive outcomes 
in regard to treating diabetes and obesity. Many techniques that 
influence ghrelin’s role in decreased insulin secretion are still in 
the experimental phase but may eventually be effective to treat 
diabetes and obesity. Ghrelin’s effects on insulin sensitivity are 
also being explored. Can regulation of ghrelin serve as a possible 
treatment option for diabetes and obesity?
Methods
The research obtained about ghrelin’s effects on the metabolism 
of diabetics and obese individuals was collected from a variety 
of sources. The majority of articles were collected using Touro’s 
library to access databases such as Pubmed, ProQuest and more. 
Additionally, other articles were found by searching Google 
scholar for relevant journals on the topic. After reviewing numer-
ous articles on ghrelin’s effects on obesity and diabetes, evidence 
was compiled to answer the research question. 
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Discussion
Ghrelin and its forms:
Ghrelin is a 28-peptide amino acid that is produced mainly in the 
stomach. This hormone is responsible for signaling hunger and 
maintaining an energy balance. Acylated ghrelin, or acyl ghrelin, 
the active form of ghrelin consists of noctanoylation on the 
third serine. This form of ghrelin is able to bind to the GHS-R1a, 
enabling it to have a biological effect in areas such as growth 
hormone secre-tion and glucose metabolism. However, most of 
our plasma circulating ghrelin is unacylated ghrelin, or des acyl 
ghrelin, which has been discovered to have biological effects as 
well (Kiewiet, et al. 2009). 
The effects of each form of ghrelin on insulin concentration and 
sensitivity has been studied. Acylated ghrelin (AG), the active 
form of ghrelin has been found to be responsible for decreased 
insulin levels, while unacylated ghrelin’s (UAG) affects are being 
studied. It has been noted that ghrelin levels have a preprandial 
increase and a postprandial decrease indicating its role as an ap-
petite stimulant (Kiewiet, et al. 2009). The hormone insulin acts 
in the opposite way, so investigators seek to explain the rela-
tionship between the two. Some studies examined the effects of 
AG and UAG on the insulin metabolism. Findings were that AG 
stimulated glucose release by hepatocytes, while UAG inhibited 
these effects. In addition, in an experiment done with adult-onset 
growth hormone-deficient patients, AG was found to decrease 
insulin sensitivity, and coinjection of UAG countered the effect. 
Thus, the circulating plasma ghrelin’s two forms act in contrasting 
ways (Ukkola, 2009).  An experiment was conducted in order to 
isolate the actions of AG and UAG. Subjects were administered 
a combination of AG and UAG and then each form of ghrelin on 
its own. The subject group consisted of 8 morbidly obese female 
Caucasians. The mean age was 45.4± 10.3 in the range of 28-62 
years old. The average BMI of the subjects was 42.4± 4.8 kg/m2 . 
This experiment was a repeated measures design in which each 
of the 8 subjects received all the experimental conditions with 
a two-week break in between. Ghrelin was administered after 
overnight fasting conditions after a saline infusion. The three ex-
periments were: administration of 200 µg of UAG on its own, 
administration of 100 µg of AG together with 100 µg UAG, and 
a placebo. Subjects were then given a 595 kcal breakfast, a similar 
lunch three hours later, and then they were free to eat what they 
pleased until midnight. Blood samples were collected to measure 
the total ghrelin, glucose, and insulin concentrations. After the 
first hour of administration, while subjects were fasting, admin-
istration of UAG on its own did not change insulin levels or glu-
cose concentrations, nor did it differ from the placebo. Receiving 
the combination of UAG and AG resulted in significantly de-
creased insulin levels as compared to UAG administration alone 
and the placebo (58.2 ± 6.3% insulin concentration when AG and 
UAG were administered combined, compared to 91.8 ± 3.0%, 
the insulin concentration when UAG was administered alone). 
This experiment tested for insulin sensitivity using the glucose 
to insulin ratio. The results indicated an almost 50% decrease in 
insulin levels and almost no change in glucose concentration. This 
demonstrated the effect of UAG to improve insulin sensitivity 
when administered along with the AG that lowered the insulin 
levels. Also, subjects with a smaller AG:UAG ratio possessed 
increased insulin sensitivity indicating the combination effect of 
coinjection of AG and UAG. This may lead to a possible treatment 
for diabetes  for many diabetics have problems with insulin sensi-
tivity. However, further research is needed to exactly determine 
insulin sensitivity, for the glucose-insulin ratio does not consider 
secretion, distribution and degradation of insulin (Kiewiet, et al. 
2009). 
However, a recent study tested the effect of AG in combination 
with UAG on insulin and glucose metabolism. Healthy volunteers 
were given pharmacological doses of AG and UAG as a bolus 
and at 210-minute intervals under fasting conditions and intra-
venous glucose administration. However, The UAG did nothing 
to plasma insulin levels after AG decreased them. This study did 
not examine but encourages further study on insulin sensitivity 
following AG and UAG administration (Barazzoni, 2014). Previous 
research tested the effects of ghrelin on inulin sensitivity by using 
the insulin-glucose ratio. Although the insulin levels stayed the 
same, the glucose levels decreased indicating greater insulin sen-
sitivity (Kiewiet, et al. 2009). Although this may not give the most 
reliable results because it does not consider other factors that 
can contribute to insulin sensitivity, it is a start in observing the 
effect that UAG has on insulin sensitivity. Nevertheless, further 
research is needed to confirm this relationship.
Insulin Sensitivity
Although it may be hypothesized that obese individuals have 
Figure 1
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elevated ghrelin levels contributing to their obesity, on the con-
trary, obese individuals have lower ghrelin concentrations than 
normal.  According to a study obese patients’ plasma active 
ghrelin levels compared to lean subjects were 180 ± 18 vs. 411 
± 57 pg/ml. Serum total ghrelin levels differed from 3650 ±408 
in obese patients and 5263 ±643 pg/ml in lean subjects. Ghrelin 
levels were correlated with insulin resistance that was calculated 
using the HOMA approach which is: insulin (micro-units/milliliter) 
× blood glucose (milllimoles/liter)/ 22.5 (Marzullo, et al. 2003). 
Similarly, in a different study, lower ghrelin levels were found in 
obese subjects. This study, shows the correlation between body 
fat and circulating ghrelin levels after obese and lean subjects 
were fed a weight maintaining diet and abstained from exercise 
two days. The results indicated that the obese subjects’ ghrelin 
levels were 32% lower than the lean subjects’. Additionally, a 
negative correlation was found between ghrelin concentration 
and body fat  (r = -.45). Insulin was also negatively correlated to 
ghrelin concentration (r = -.45) (Tscöp, et al. 2001). Since ghrelin 
is responsible for energy balance and homeostasis, this study is 
consistent with present knowledge. Obese individuals have stable 
energy levels so the body lowers the ghrelin response. However, 
although the circulating ghrelin levels are minimized, its effects on 
insulin and body fat are still present. 
Studying children with type 1 diabetes mellitus (T1DM) indicated 
lower levels of total ghrelin in comparison to healthy subjects. 
Also, higher levels of AG contributed to lower insulin levels and 
greater insulin resistance. Therefore, a possible way the body 
protects diabetics from hyperglycemia can be the decreased con-
centration of circulating ghrelin. Insulin therapy after four months 
elevated ghrelin levels in twenty children with T1DM (Ukkola, 
2009). This can indicate the body considering lower ghrelin levels 
unnecessary due to the insulin therapy.
Although we can understand how insulin resistance is a problem 
in diabetic patients, obesity can contribute to insulin resistance as 
well. One way in which obesity contributes to insulin resistance 
is through the immune system’s activation by obesity. Adipose 
tissue macrophages produce pro-inflammatory cytokines that 
can lead to insulin resistance by blocking insulin action in adipose 
tissue, skeletal muscle, and liver. Therefore, ghrelin as a possible 
therapeutic option can improve both diabetics and obese individ-
uals’ health (Ota, 2014). 
Ghrelin’s Metabolic Effects
An experiment examined ghrelin levels in lean, obese, diabetic 
and nondiabetic subjects. Blood samples were collected after 
overnight fasting and again after monitored eating. Compared 
to normal weight subjects, mean plasma ghrelin concentrations 
were 225% for those with anorexia nervosa and 68% for obese 
subjects. A negative correlation exists between BMI and plasma 
ghrelin concentration. The body maintains homeostasis by de-
creasing ghrelin levels in the presence of positive energy balance. 
When the body has excess energy from nutrition, the ghrelin lev-
els are decreased to postpone hunger. This justifies the postpran-
dial, or after eating a meal, decrease of ghrelin levels (Shiiya, et al. 
2002). Ghrelin’s effects on feeding and energy balance refer to 
the ghrelin produced in the stomach; however, the pancreas also 
produces ghrelin contributing to glucose metabolism. Ghrelin 
is an insulinostatic hormone, meaning it controls the release of 
insulin. Ghrelin levels were compared from the pancreatic vein 
that leaves the pancreas and the pancreatic artery that brings 
new blood to the pancreas. Results showed 8 times the amount 
of ghrelin levels in the pancreatic vein, indicating the pancreas 
produces that ghrelin (Yada, et al. 2014). The GHS-R1a, the ghrelin 
receptor, is located on pancreatic islet cells. Ghrelin binds to the 
receptor and decreases insulin release from the cell and elevates 
blood glucose concentrations. When glucose concentrations rise 
from 2.8 mM to 8.3 mM, insulin release from β cells is stimulated. 
The intensification of Ca2+ concentrations, stimulated by glucose 
metabolism is a crucial step in insulin secretion. However, insulin 
release is weakened when ghrelin is exogenously administered at 
a high concentration of 10 nM. Ghrelin suppresses the peaks of 
Ca2+ by increasing amplitudes of Kv currents that block the in-
flux of Ca2+ ions into the cell thereby slowing down the process 
of glucose-induced insulin release (Yada, et al. 2008). 
 
Research has proven that ghrelin’s effect on the Kv channels re-
sult from decreased cAMP levels. cAMP, cyclic AMP (adenosine 
monophosphate) signaling plays one of the most vital roles in in-
sulin secretion from beta cells (Kashima,et al. 2001). Ghrelin uses 
G-protein Gαi2 to obstruct the cAMP response to glucose me-
tabolism. cAMP activates PKA, protein- kinase-A, and suppresses 
Kv currents in islet cells. Since the insulinostatic effect of ghrelin 
Figure 2
The binding of ghrelin to GHS-R reduces cAMP expression and in-
creases the K+ current. This slows down the influx of Ca2+ into the 
cell, leading to a decreased insulin secretion response to glucose 
metabolism� (Yada, et al� 2014)
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occurs through the cAMP pathway, one possible way to minimize 
it is by presenting cAMP analogues along with ghrelin. One mole-
cule used in testing the effects of cAMP analogs on insulin secre-
tion is 6-Phe-cAMP. In the presence of cAMP analogs, ghrelin has 
no effect on insulin secretion. Hence, by reinstating the cAMP 
activation pathway in the presence of ghrelin, diabetics can expe-
rience enhanced insulin secretion (Dezaki, et al. 2011). This study 
demonstrates a new remedial approach to reducing ghrelin’s ef-
fects. cAMP analogs may aid diabetes by enhancing insulin secre-
tion in pancreas islet. 
Ghrelin Antagonism
Since type 2 diabetics do not have enough insulin, anti-ghrelin 
treatments can enhance insulin secretion. In obesity, insulin resis-
tance is a problem, so eliminating ghrelin can produce a positive 
effect on hyperglycemia. Ghrelin’s affects on insulin and glucose 
metabolism, food intake, and body weight all need to be assessed 
in order to determine if antagonism of ghrelin can relieve symp-
toms of diabetics and obese individuals. One popular method 
used to remove ghrelin’s affects is by antagonism of the GHS-R. 
If the receptor does not accept ghrelin, it has no effect on the 
pancreatic islets. In an experiment using fasted mice, ghrelin re-
ceptor antagonists [D-Lys3]-GHRP-6 enhanced insulin secretion 
and lowered blood glucose levels. This research indicated that a 
ghrelin blockade increases insulin release to help maintain normal 
glucose concentrations (Yada, et al. 2008). Experiments done with 
gastrectomized mice, that lack stomach-derived ghrelin, show the 
role of pancreatic ghrelin in the insulin response. After GHS-R 
antagonist was administered, both groups of mice showed the 
same increased insulin response. This proves that the pancreatic 
ghrelin is responsible for these effects. Therefore, targeting the 
GHS-R can be a therapeutic approach in enhancing insulin secre-
tion (Dezaki, et al. 2006). Administering intra-peritoneal ghrelin 
antagonist to mice also decreased food consumption (Asakawa, 
et al. 2003). These findings can be beneficial in aiding obese indi-
viduals control their food intake. 
Additionally, an experiment done on mice implied ghrelin’s effects 
on body weight, insulin levels, and blood glucose concentrations. 
Injection of ghrelin twice a day for five days increased body 
weight in mice compared to the control. Depending on the diet 
and whether the mouse received ghrelin or saline, determined 
the increase in body weight. For example, one group of mice 
were fed a high fat diet and given saline. These mice exhibited a 
.60 g/day increase in body weight, while those fed a high fat diet 
with ghrelin had a .92 g/day increase. Serum cholesterol and insu-
lin levels increased and glucose concentration increased as well. 
The same experiment tested how ghrelin antagonist, [D-Lys3]-
GHRP-6, affected the same factors. After 7 days of administra-
tion to obese mice, weight gain, fat pad mass, and blood glucose 
concentrations decreased (Asakawa, et al. 2003). This study does 
not seem to be consistent with other research that has linked 
elevated ghrelin to decreased plasma insulin secretion; but a 
moderate increase in glucose concentration was observed. This 
can indicate a case of insulin resistance instigated by an increase 
in free fatty acids (FFA) that are known to contribute to insulin 
resistance. GHS-R antagonists increased insulin sensitivity and 
reduced glucose levels. In addition, it simultaneously decreased 
FFA concentration aiding in fostering insulin sensitivity (Asakawa, 
et al. 2003).
One class of drugs that is being studied as possible ghrelin recep-
tor antagonists are quinazolinone derivatives. In the lab, quinazoli-
none derivative 1 was discovered to have affinity to GHS-R1a. Yet, 
it was found that the molecule had agonistic binding to the recep-
tor rather than the desired antagonistic affect. Alkylation of the N 
group on the molecule altered its functionality by transforming 
it into a GHS-Rla antagonist. Piperdine-substituted quinazolinone 
derivatives that are phenyl or phenoxy substituted were found to 
act as GHS-R antagonists (Del-porte, 2011).
In a structure-activity relationship study, many derivatives of the 
compound were tested for their effects in vivo. Two quinazoli-
none compounds that were used for study were compounds 
26 and 43. These antagonists were administered at doses 3, 10, 
and 30 mg/kg. While compound 26 lowered body weight at the 
10 mg/kg dose, compound 43 only was effective at 30 mg/kg. 
Compound 26 at 30 mg/kg is known as the first orally adminis-
tered GHS-R antagonist possible to induce weight loss in animals. 
This renders it a feasible way to treat obesity, a leading cause of 
diabetes. Compound 26 administered at the highest dose had 
similar effects to an anti-obesity drug that is still under evaluation 
by the FDA, CB1 antagonist rimonabant, 5-(4-choophenyl-1-(2,4-
dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-car-
boxamide. This study also tested glucose tolerance. Both com-
pounds decreased glucose excursion by around 20%. However, 
the cause be-hind these decreased blood glucose levels, was 
not tested for. The study would like to go further in confirming 
that this result from the GHS-R antagonist stemmed from an 
enhanced insulin secretion (Rudolph, et al. 2007). This research 
1 2
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Figure 3
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brings practical application of a drug that may be available to help 
treat obesity and diabetes. As a receptor antagonist, it minimizes 
ghrelin’s insulinostatic effects and enhances glucose metabolism. 
Immunoneutralization
Immunoneutralization of ghrelin also is a potential method of 
enhancing insulin secretion. Creating a vaccine to stimulate an-
tibody production against acylated ghrelin may be a viable treat-
ment for obese individuals. However, when a trial was conducted 
using a CYT-009 Ghr Qb vaccine, antibodies were developed, but 
weight stayed the same (Delporte, 2011). In another instance, 
mice were immunized against ghrelin to produce an antibody 
response. After being fed identical diets, the rats with more 
ghrelin-specific antibodies gained less weight per calorie ingested. 
Since their food intake did not vary from other control mice, 
this experiment shows that ghrelin produces a metabolic change 
rather than feeding changes. However, ghrelin has been known 
to increase feeding in a high-fat diet, these mice were given low-
fat, less appetizing meals. This could be a factor that might have 
influenced the ghrelin-vaccinated mice’s feeding habits, so the re-
liability of their conclusion is questionable. Additionally, there can 
be possible draw-backs to this course of treatment. Long-term 
or other side effects of eliminating ghrelin are unclear. It may 
have possible ramifications on energy balance that is regulated by 
ghrelin. The absoluteness of inactivating ghrelin by use of antibod-
ies is also irreversible, unlike ghrelin receptor antagonism that 
can be stopped when undesired effects occur. Another obstacle 
that we may be facing with immunoneutralization is the negative 
feedback loop of the body producing more ghrelin to compen-
sate for lack of ghrelin signals. Although the immediate results of 
an anti-ghrelin vaccine may look promising, further research is 
needed to con-firm the safety and reliability of this method to 
reduce body weight. Controlling the immune response can keep 
ghrelin antibodies from getting out of hand (Carl-son, Cummings, 
2006). However, until research can safely develop and monitor 
such a vaccine, it would be best to put this method on hold. 
Ghrelin Knockout
An alternative to a ghrelin vaccine is the ghrelin knockout model. 
The ghrelin gene is deleted from rats and they are then mon-
itored for feeding habits, metabolism, weight gain, and glucose 
concentration. One point to remember is the unknown effects 
of ghrelin’s complete absence from the body. In one experiment, 
ghrelin’s effects on insulin secretion were tested using ghrelin 
knockout mice. In particular, glucose-induced insulin release was 
higher in knockout mice. On the contrary, basal insulin levels 
remained the same in knockout and wild-type mice. Therefore, 
ghrelin knockout mice had improved insulin responses to glu-
cose. Afterwards, an insulin tolerance test (ITT) was given to both 
groups of mice. No significant differences were found between 
them. The experiment advanced to testing the effects of a high-fat 
diet, known to increase glucose concentrations. When fed a high 
fat diet, blood glucose levels increased in wild-type mice, and no 
in-crease was identified in the knockout mice. This can be at-
tributed to enhanced insulin secretion in response to elevated 
glucose levels. After the wild-type mice did a glucose tolerance 
test (GTT), mice with a high-fat diet showed higher glucose con-
centration levels compared to a control diet, implicating glucose 
intolerance. On the other hand, the ghrelin knockout mice exhib-
ited no difference in glucose tolerance between the high-fat diet 
and the control group. However, there was an increased insulin 
response in the mice fed a high-fat diet (Dezaki, et al. 2006). This 
research shows ghrelin’s role in glucose-insulin metabolism. In 
the ab-sence of ghrelin, increased insulin levels and improved glu-
cose tolerance were found. Although ghrelin knockout cannot be 
done to humans, it serves as an indication of ghrelin’s metabolic 
effects. Regulating ghrelin levels in obese people can possibly im-
prove their body weight and glucose tolerance.  
GOAT
Ghrelin O-acyltransferase is a membrane-bound O-acyltransferace. 
It catalyzes the octanoylation of ghrelin allowing it to be acylated 
and able to connect with the GHS-R1a receptor. Since it catalyz-
es ghrelin to be in its active form, one idea is to target GOAT 
to slow the process of the body producing acylated ghrelin. In 
GOAT knockout models, there is no acylated ghrelin found circu-
lating (Pulk-kinen, et al. 2010). As discussed earlier, studies show 
that unacylated ghrelin counteracts acylated ghrelin’s effect on 
insulin, and did nothing to insulin metabolism when administered 
on its own (Kiewiet, et al. 2009). So, inhibiting GOAT action can 
minimize the effects that acylated ghrelin has on insulin and glu-
cose metabolism. 
One method studied to inhibit GOAT is the administration of 
GO-CoA-Tat in mice. The GHS-R binding property of ghrelin 
is determined by the octanoylation on serine 3, making it acyl 
ghrelin. This inhibitor was found to be most active in binding to 
GOAT. After administering GO-CoA-Tat to mice at a 40 mg/kg 
dose, acyl ghrelin levels decreased while des acyl ghrelin levels 
remained unchanged. Additionally, after 1 month, weight gain 
due to decreased fat mass was assessed in the treated mice. 
Interestingly, no difference in weight was found compared to 
ghrelin knockout mice. This indicates that GOAT inhibition may 
have similar effects to ghrelin knockout. The mice’s response to 
glucose was measured to observe the effects of GO-CoA-Tat. 
The insulin response was in-creased and blood glucose levels 
subsequently decreased. This did not occur in ghrelin knockout 
mice thereby reinforcing the mechanism of GOAT inhibition to 
prevent ghrelin’s acylation (Taylor, et al. 2012). Additionally, use of 
this GOAT inhibitor may be a better option than using a ghrelin 
antagonist. Some advantages that a study done by Barnett et al. 
in 2010 explains  that GO-CoA-Tat does not need to cross the 
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blood brain barrier unlike the GHS-R antagonist which targets 
receptors in the brain as well. Additionally, there is no feedback 
of the body trying to compensate by producing extra acylated 
ghrelin to bind to the receptors. Another reason given is that 
targeting an enzyme like GOAT may be safer than targeting a 
widespread receptor (Barnett, et al. 2010). However, GOAT is 
still being studied and its use in treatment is not yet confirmed. 
Further experimentation would need to be done to examine the 
viability of such a method of treatment in humans, and the possi-
ble negative side effects of a drug using this mechanism. 
In conclusion, currently research is in the process of determin-
ing the possibilities of using the ghrelin system to treat or cure 
diabetes and obesity. No definite answer can be given about its 
viability in human subjects as most experimentation is done in 
mice. However, the facts have been proven. Ghrelin’s influences 
on insulin secretion, blood glucose concentration, weight-gain, 
and fat mass have been assessed in various studies. The regulation 
of ghrelin by reducing its impact on pancreatic islets or by elimi-
nating it altogether have been found to enhance insulin secretion 
and lead to less weight gain. Therefore, further research on the 
pharmacological effects of drugs used to regulate ghrelin’s effects 
may lead to a more certain conclusion.
Legend
AG: Acylated ghrelin UAG: Unacylated ghrelin
GHS-R: Growth hormone secretagogue recep-tor
GOAT: Ghrelin O-acyltransferace
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